Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?
Current standard of care for treatment of CML is based on tyrosine kinase inhibitors (TKI's). Imatinib is most frequently used first line tyrosine kinase inhibitor. Various side effects of TKI's are known, but some may still be unknown. We are reporting three cases of CML who developed tuberculosis while on treatment with imatinib or dasatinib. Two cases developed CNS tuberculosis and other one was tubercular pleural effusion. These cases indicate that imatinib and other TKI's probably interfere with immunological functions and predispose patients for tuberculosis.
['Verma|Shailendra Prasad|SP|', 'Tripathi|Anil Kumar|AK|', 'Kumar|Nidhish|N|', 'Gupta|Suneel Kumar|SK|']
D000328:Adult D000074322:Antineoplastic Agents, Immunological D015984:Causality D000069439:Dasatinib D057915:Drug Substitution D006801:Humans D000068877:Imatinib Mesylate D007166:Immunosuppressive Agents D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive D008297:Male D008875:Middle Aged D009169:Mycobacterium tuberculosis D010996:Pleural Effusion D047428:Protein Kinase Inhibitors D016896:Treatment Outcome D020306:Tuberculosis, Central Nervous System D014396:Tuberculosis, Pleural
Tyrosine kinase inhibitors (TKI's) CNS tuberculosis Pleural effusion Chronic myeloid leukemia (CML)